Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocriplasmin in symptomatic vitreomacular adhesion
NCT01889251Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jul 2013
- Primary completion
- Sep 2014
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ocriplasmin in vitreomacular adhesion (VMA), sponsored by Alcon Inc.. Started Jul 2013; status: completed.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular adhesion (VMA)
Beyond the preview
Go deeper on NCT01889251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889251.